Profound Medical Corp.

PROF Nasdaq SEC CIK 1628808
Follow Profound Medical Corp. Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $9.8M +94.3% vs same quarter last year
Net income −$7.7M +3.2% vs same quarter last year
EPS, diluted −$0.21 +19.2% vs same quarter last year
Operating cash flow −$5M +47.9% vs same quarter last year
Revenue by quarter
$4M
$2.3M
$2M
$5.1M
$6.7M
$5.3M
$2.5M
$9.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
$0$5M$10M$15M$20MFY22FY23FY24FY25
Show the numbers
YearRevenue
FY25$16.1M
FY24$9.7M
FY23$5.9M
FY22-
MarginsShare of revenue
  • Gross margin
  • Operating margin
−600%−400%−200%0%200%FY22FY23FY24FY25
Show the numbers
YearGross marginOperating margin
FY2570.8%−256.3%
FY2472.2%−339.4%
FY2373.1%−485.7%
FY22--